| camrelizumab based treatment | nivolumab based treatment | pembrolizumab based treatment |
| camrelizumab alone | nivolumab alone | pembrolizumab alone | pembrolizumab plus SoC |
| mEC - (neo)adjuvant (NA) 1 | | | | |
| mEC - 1st line (L1) 1 | | | | |
| mEC - 2nd line (L2) 3 | | | | |
Comparator:
vs placebo; vs placebo plus SoC; vs Standard of Care (SoC);
Risk of bias:
low;
some concerns;
high;
NA;